'Very over sold': Biotech brags about PhII Alzheimer's data, but experts are underwhelmed
In a field now defined by Biogen’s Aduhelm — and the storm of controversy around it — what constitutes “industry-leading” data for an Alzheimer’s drug?
Alzheon, a little biotech developing an oral amyloid-clearing tablet, is taking a stab at it.
Reporting six-month data from a Phase II biomarker trial involving 84 patients, Alzheon announced that ALZ-801, or valiltramiprosate, spurred a 29% reduction in a biomarker called plasma p-tau181 — which it said is seven-fold greater than that triggered by other anti-amyloid antibodies. Paired with “significant improvement” in a memory test while not specifying how much, the numbers validate its approach and offer “a clear path forward with our molecules,” according to CEO Martin Tolar.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.